Smoking Cessation Treatment With Transdermal Nicotine Replacement Therapy - 1

Smoking Cessation Treatment With Transdermal Nicotine Replacement Therapy

The purpose of this study is to look at how feasible it is to incorporate a state-of-the-art smoking cessation treatment program into community substance abuse treatment programs and its impact on substance abuse and cigarette smoking.

Study Overview

• Status: Completed
• Conditions: Tobacco Use Disorder
• Intervention / Treatment: Drug: nicotine transdermal system

• Study Type: Interventional
• Enrollment: 585
• Phase: Phase 3

Contacts and Locations

Study Locations

• United States
  • California
    • Los Angeles, California, United States, 90016
      • Matrix Institute on Addictions
    • Tarzana, California, United States, 91356
      • Tarzana Treatment Center
  • Florida
    • Miami, Florida, United States, 33156
      • Spectrum
    • Orlando, Florida, United States, 32805
      • Center for Drug Free Living
  • Michigan
    • Ann Arbor, Michigan, United States, 48103
      • Chelsea Arbor Addictions Treatment Center
    • Detroit, Michigan, United States, 48207
      • Psychiatry and Behavioral Medicine Professionals I
  • New York
    • Long Island City, New York, United States, 11101
      • Narco Freedom (Bridge Plaza)
    • New York, New York, United States, 10029
      • Mount Sinai Medical Center
    • New York, New York, United States, 10019
      • St. Luke's Roosevelt Hospital Center
    • New York, New York, United States, 10025
      • St. Luke's Roosevelt Hospital Center, Womens
  • North Carolina
    • Concord, North Carolina, United States, 28001
      • Piedmont Behavioral Healthcare
    • Wilmington, North Carolina, United States, 28412
      • Coastal Horizons Center, Inc.
  • South Carolina
    • Pickens, South Carolina, United States, 29671
      • Behavioral Health Services of Pickens County

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 99 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patient is alcohol or drug dependent, in Outpatient Drug-Free or Opiate Substitute program and is interested in quitting smoking

Exclusion Criteria:

• Patient is psychotic
• Use of smokeless tobacco
• Use of other smoking cessasation product
• Pregnancy
• Patient has hyper-tension, heart problems, or skin condition

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Drug use
Smoking Cessation

Collaborators and Investigators

• Sponsor: New York University
• Investigators: Principal Investigator: Malcolm Reid, Ph.D., New York University

Study record dates

Study Major Dates

• Study Start: April 1, 2003
• Primary Completion (Actual): July 1, 2004
• Study Completion (Actual): July 1, 2004

Study Registration Dates

• First Submitted: August 12, 2003
• First Submitted That Met QC Criteria: August 12, 2003
• First Posted (Estimate): August 13, 2003

Study Record Updates

• Last Update Posted (Estimate): January 12, 2017
• Last Update Submitted That Met QC Criteria: January 11, 2017
• Last Verified: April 1, 2010

More Information

Terms related to this study

• Keywords: nicotine dependence
• Additional Relevant MeSH Terms: Mental Disorders; Chemically-Induced Disorders; Substance-Related Disorders; Tobacco Use Disorder; Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Autonomic Agents; Peripheral Nervous System Agents; Cholinergic Agents; Ganglionic Stimulants; Nicotinic Agonists; Cholinergic Agonists; Nicotine
• Other Study ID Numbers: NIDA-CTN-0009-1